Antitope is a wholly owned subsidiary of the PolyTherics group and is focused on providing services and technologies to enable the development of better biopharmaceuticals.
Antitope was formed in Cambridge, UK, in 2004 in order to advance the research of the founders by developing proprietary technologies for immunogenicity prediction, antibody humanization and engineering of therapeutic proteins. We have entered into agreements with pharmaceutical and biotechnology companies worldwide to apply our technologies for the development of improved biologics. Products that have been generated using our technologies have progressed to the clinic.
Our services are tailored for each project to ensure that the objectives are met or exceeded. Experienced project teams are assigned to each study focusing on progressing projects through to results in the minimum amount of time. Our clients uniformly judge us as professional and attentive partners who deliver quality results in a timely manner.
Antitope became part of the PolyTherics group in July 2013, creating a leading provider of solutions to enable the development of better biopharmaceuticals.